{
    "persona": "neutral",
    "model": "mixtral:8x7b-instruct-v0.1-q6_K",
    "topic": "healthcare",
    "language": "English",
    "text": "Exciting news for migraine sufferers! Long-term data shows atogepant 60mg daily reduces monthly migraine days by 8.5 on average, with 70% of patients achieving a 50% reduction at weeks 13-16, maintained over 48 weeks. Safety and tolerability confirmed at 52 weeks.",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "3b49e61e269930aeca46a088dea7123c72575f546c5b6ec6"
}